Drug intelligence / Profile preview

AGAcell

Development stage: Preclinical
Lead developer: Ideeea Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intradermal

Overview

**AGAcell** is a preclinical intradermal allogeneic mesenchymal stem-cell therapy candidate sponsored by Ideeea Therapeutics for androgenetic alopecia. The formulation contains GMP-grade allogeneic mesenchymal stem cells with ATP and is intended to modulate the dihydrotestosterone-androgen receptor axis while improving the follicular microenvironment through effects on oxidative stress, inflammation, and vascularization. Farmalíder lists preclinical safety studies for 2025–2026 and a planned Phase I study in 2026–2027. ([farmalider.com](https://farmalider.com/wp-content/uploads/2025/11/PAGS-tript-agacell_v4-LV.pdf))

Brand names: AGAcell

Beyond the preview

Go deeper on AGAcell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGAcell.

Explore the full profile